Oxidative stress and inflammatory response biomarkers in dogs with mammary carcinoma

Pathology Research and Practice

Volumn 211, Issue 9, 2015, Pages 677-681

  Machado, Vanessa S ^a   Crivellenti, Leandro Z ^b,c   Bottari, Nathieli B ^a   Tonin, Alexandre A ^d   Pelinson, Luana P ^a   Borin Crivellenti, Sofia ^b   Santana, Aureo E ^b   Torbitz, Vanessa D ^a   Moresco, Rafael N ^a   Duarte, Thiago ^a   Duarte, Marta M M F ^e   Schetinger, Maria Rosa C ^a   Morsch, Vera M ^a   Jaques, Jeandre A ^f   Tinucci Costa, Mirela ^b   Da Silva, Aleksandro S ^a,g  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c Faculty of Medicine of Franca (UNIFRAN)   (Brazil)

^d UNIVERSIDADE DO OESTE DE SANTA CATARINA   (Brazil)

^e UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^f FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

^g SANTA CATARINA STATE UNIVERSITY   (Brazil)

Author keywords

Breast cancer; Immune response; Oxidative stress; Pathogenesis

Indexed keywords

ADENOSINE DEAMINASE; CHOLINESTERASE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 16; NITRIC OXIDE SYNTHASE; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; ADVANCED OXIDATION PROTEIN PRODUCT; ANTIOXIDANT; AUTACOID; CYTOKINE; NITRIC ACID DERIVATIVE; NITRITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CONTROLLED STUDY; DISEASE ASSOCIATION; DOG; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN DETERMINATION; ANIMAL; BLOOD; BREAST TUMOR; DOG DISEASE; IMMUNOLOGY; METABOLISM; PATHOLOGY; UDDER; VETERINARY;

ADENOSINE DEAMINASE; ADVANCED OXIDATION PROTEIN PRODUCTS; ANIMALS; ANTIOXIDANTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; BUTYRYLCHOLINESTERASE; CYTOKINES; DOG DISEASES; DOGS; FEMALE; INFLAMMATION MEDIATORS; MAMMARY GLANDS, ANIMAL; NEOPLASM GRADING; NITRATES; NITRITES; OXIDATIVE STRESS;

EID: 84957729557     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2015.06.011     Document Type: Article

References (62)

1. Henderson B.E., Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis 2000, 21:427-433.
2. Ingvarson S. Breast cancer: introduction. Cancer Biol. 2001, 11:323-326.
3. Bostock D.E. Canine and feline mammary neoplasms. Br. Vet. J. 1986, 142:506-515.
4. Peleteiro M.C. Tumores mamários na cadela e na gata. Rev. Portug. Ciênc. Vet. 1994, 89:10-29.
5. Misdorp W. Tumors of the mammary gland. Tumors in Domestic Animals 2002, 575-606. University of California, Iowa State. fourth ed. D.J. Meuten (Ed.).
6. Fonseca C.S., Daleck C.R. Neoplasias mamárias em cadelas: influência hormonal e efeitos da ovário-histerctomia como terapia adjuvante. Cienc. Rural 2000, 30:731-735.
7. Zuccari D.A.P.C., Santana A.E., Rocha N.S. Fisiopatologia da neoplasia mamária em cadelas - revisão. Clin. Vet. 2001, 32:50-54.
8. Silva A.E., Serakides R., Cassali G.D. Carcinogênese Hormonal e neoplasias hormÔnio-dependentes. Ciênc. Rural 2004, 34:625-633.
9. Nowak M., Madej J.P., Rossowska J., et al. Involvement of CD8+cells in protective mechanisms in canine mammary adenocarcinomas (short communication). Bull. Vet. Inst. Pul. 2007, 51:445-448.
10. Whitford P., Mallon E.A., George W.D. Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br. J. Cancer 1990, 62:971-975.
11. Altomaa S., Lipponen P., Eskelinen M., et al. Lymphocytes infiltrates as a prognostic variable in female breast cancer. Eur. J. Cancer 1992, 28:59-864.
12. Camp B.J., Dyhrman S.T., Memoli V.A., et al. In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann. Surg. Oncol. 1996, 3:176-184.
13. Sica A., Allavana P., Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008, 264:204-215.
14. Ben-baruch A. Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 2003, 31:31-36.
15. Mantovani A. Inflammation and cancer: the macrophage connection. Medicina 2007, 67:32-34.
16. Lin E.Y., Pollard J.W. Minireview role of infiltrated leucocytes in tumour growth and spread. Br. J. Cancer 2004, 90:2053-2058.
17. Coussens L.M., Werb Z. Inflammatory cells and cancer: think different!. J. Exp. Med. 2001, 193:23-26.
18. Aspord C., Pedroza-Gonzalez A., Gallegos M., et al. Breast Cancer Instructs Dendritic Cells to Prime Interleukin 13-secreting CD4+T Cells that Facilitate Tumor Development 2007, 1037-1047. The Rockefeller University Press, 204.
19. Yoo S.Y., Lee S.Y., Yoo N.C. Cytokine expression and cancer detection. Med. Sci. Monit. 2009, 15:49-56.
20. Khanduja K.L., Sohi K.K., Pathak C.M., Kaushik G. Nimesulide inhibits lipopolysaccharide-induced production of superoxide anions and nitric oxide and iNOS expression in alveolar macrophages. Life Sci. 2006, 78:1662-1669.
21. Lima E.S., Abdalla D.S.P. Peroxidação lipídica: mecanismos e avaliações em amostras biológicas. Rev. Bras. Ciênc. Farmacêut. 2001, 37(3).
22. Briganti S., Picardo M. Antioxidant activity, lipid peroxidation and skin diseases. Eur. Acad. Dermatol. 2003, 17:663-669.
23. Ralevic V., Burnstock G. Involvement of purinergic signalling in cardiovascular diseases. Drug News Perspect. 2003, 16(3):40-133.
24. Borovikova L.V., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405(6785):458-462.
25. Das U.N. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med. Sci. Monit. 2007, 13(12):214-221.
26. Balis M.E. Adenosine deaminase na malignant cells. Anna. N.Y. Acad. Sci. 1985, 451:142-149.
27. Nieto-Cerón S., et al. Analysis of cholinesterases in human prostate and sperm implication in cancer and fertility. Chem. Biol. Interact. 2010, 187:432-435.
28. Soreq H., Seidman S. Acetylcholinesterase new roles for an old actor. Nat. Rev. Neurosci. 2001, 2:294-302.
29. Ruiz-Espero F., et al. Cholinesterase activity and acetylcholinesterase glycosylation are altered in human breast cancer. Breast Cancer Res. Treat. 2002, 72:11-22.
30. Tatsch E., Bochi G.V., Pereira R.S., Kober H., Oliveira J.R., Moresco R.N. A simple and inexpensive automated technique for measurement of serum nitrite/nitrate. Clin. Biochem. 2011, 44:348-350.
31. Hanasand M., Omdal R., Norheim K.B., Goransson L.G., Brede C. Improved detection of advanced oxidation protein products in plasma. Clin. Chim. Acta 2012, 413:901-906.
32. Benzie I.F.F., Strain J.J. The ferric reducing ability of plasma (FRAP) as a measure of "Antioxidant Power": The FRAP Assay. Anal. Biochem. 1996, 239:70-76.
33. Giusti G. Adenosine deaminase. Methods of Enzymatic Analysis 1974, 1092-1099. Academic Press, New York. H.U. Bergmeyer (Ed.).
34. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
35. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
36. Nicolini A., Carpi A., Rossi G. Cytokines in breast cancer. Cytok. Growth Fact. Rev. 2006, 17(5):325-337.
37. Goldberg J.E., Schwertfeger K.L. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr. Drug Targets 2010, 11:1133-1146.
38. Kim J.H., Yu C.H., Yhee J.Y., Sur J.H. Lymphocyte infiltration, expression of interleukin (IL)-1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours. J. Comp. Path. 2010, 142:177-186.
39. Miles D.W., Happerfield L.C., Naylor M.S., Bobrow L.G., Rubens R.D., Balkwill F.R. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int. J. Cancer 1994, 56:777-782.
40. Sheen-Chen S.M., Chen W.J., Eng H.L., Chou F.F. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res. Treat. 1997, 43:211-215.
41. Alshaker H.A., Matalka K.Z. IFN-γ, IL-17 and TGF-b involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int. 2011, 11:33.
42. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006, 836-848.
43. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
44. Beatty G.L., Paterson Y. IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+T cells requires tumor responsiveness to IFN- γ. J. Immunol. 2001, 166:2276-2282.
45. Dunn G.P., Ikeda H., Bruce A.T., Koebel C., Uppaluri R., Bui J., Chan R., Diamond M., White J.M., Sheehan K.C., Schreiber R.D. Interferon-γ and cancer immunoediting. Immunol. Res. 2005, 32:231-245.
46. Yu W.G., Ogawa M., Mu J., Umehara K., Tsujimura T., Fujiwara H., Hamaoka T. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J. Leukoc. Biol. 1997, 62:450-457.
47. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7556-7561.
48. Piwowar A. Biochemical and clinical aspects of advanced oxidation protein products in kidney diseases and metabolic disturbances. Postepy Hig. Med. Dosw 2014, 68:179-190.
49. Sbarouni E., Georgiadou P., Voudris V. Ischemia modified albumin changes: review and clinical implications. Clin. Chem. Lab. Med. 2011, 49:177-184.
50. Knowles R.G., Moncada S. Nitric oxide synthases in mammals. Biochemistry 1994, 298:249-258.
51. Ohshima H., Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutation 1994, 305:253-264.
52. Lala P.K. Significance of nitric oxide in carcinogenesis, tumor progression and cancer therapy. Cancer Metast. Rev. 1998, 17:1-6.
53. Tschugguel W., Schneeberger C., Unfried G., Czerwenka K., Weninger W., Mildner M., Gruber D.M., Sator M., Waldhor T., Huber J.C. Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade. Breast Cancer 1999, 56:145-151.
54. Thomsen L.L., Lawton F.G., Knowles R.G., Beesley J.E., Riveros-Moreno V., Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 1994, 54:1352-1354.
55. Iwao Y., Anraku M., Hiraike M., Kawai K., Nakajou K., Kai T., Suenaga A., Otagiri M. The structural and pharmacokinetic properties of oxidized human serum albumin and advanced oxidation protein products (AOPP). Drug Metab. Pharmacokinet. 2006, 21:140-146.
56. Atabek M., Keskin M., Yazici C., et al. Protein oxidation in obesity and insulin resistance. Eur. J. Pediatr. 2006, 165:753-756.
57. Piwowar A., Knapik-Kordecka M., Warwas M. Markers of oxidative protein damage in plasma and urine of type 2 diabetic patients. Br. J. Biomed. Sci. 2009, 66:194-199.
58. Sener D.E., Gönenç A., Akinci M., Torun M. Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem. Funct. 2007, 25:377-382.
59. Rao A.A., Sridhar G.R., Das U.N. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med. Hypoth. 2007, 69:1272-1276.
60. Da Silva A.S., Tonin A.A., Camillo G., Vogel F.F., et al. Relationship between butyrylcholinesterase activity and liver injury in mice acute infected with Toxoplasma gondii. Pathol. Res. Pract. 2013, 209:95-98.
61. Lal H., Munjial S.K., Wig U., Saini A.S. Serum enzymes in head and neck cancer III. J. Laryngol. Otol. 1987, 101:1062-1065.
62. Aghaei M., Karami-Tehrani F., Salami S., Atri M. Adenosine deaminase activity in the serum and malignant tumors of breast cancer: the assessment of isoenzyme ADA1 and ADA2 activities. Clin. Biochem. 2005, 38:887-891.